Zobrazeno 1 - 10
of 1 635
pro vyhledávání: '"C. J. j"'
Autor:
C. M. L. Zegers, A. Swinnen, C. Roumen, A. L. Hoffmann, E. G. C. Troost, C. J. J. van Asch, L. Brandts, I. Compter, E. M. T. Dieleman, J. B. Dijkstra, M. Granzier, M. Hendriks, P. Hofman, R. M. A. Houben, B. Ramaekers, H. E. Ronner, R. P. W. Rouhl, S. van der Salm, R. G. C. Santegoeds, J. J. Verhoeff, G. L. Wagner, J. Zwemmer, OEMG Schijns, A. J. Colon, D. B. P. Eekers
Publikováno v:
Trials, Vol 25, Iss 1, Pp 1-11 (2024)
Abstract Introduction The standard treatment for patients with focal drug-resistant epilepsy (DRE) who are not eligible for open brain surgery is the continuation of anti-seizure medication (ASM) and neuromodulation. This treatment does not cure epil
Externí odkaz:
https://doaj.org/article/7bd0effe7144472f968ecee8be5b7080
Publikováno v:
BMC Health Services Research, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background Generally, a significant portion of healthcare spending consists of out-of-pocket (OOP) expenses. Patients indicate that, in practice, there are often some OOP expenses, incurred when they receive medical care, which are unexpecte
Externí odkaz:
https://doaj.org/article/f8db39cb28c7489599f572d5fa98dd06
Publikováno v:
Journal of Pharmaceutical Policy and Practice, Vol 13, Iss 1 (2020)
Drug repositioning is the scientific strategy of investigating existing drugs for additional clinical indications. The advantages of drug repositioning are that it benefits patients and that it adds new indications to existing drugs for lower costs c
Externí odkaz:
https://doaj.org/article/e16e237bbb4e40a8852f43f41c583754
Autor:
A. van Ommen-Nijhof, I. R. Konings, C. J. J. van Zeijl, C. A. Uyl-de Groot, V. van der Noort, A. Jager, G. S. Sonke, On behalf of the SONIA study steering committee
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-7 (2018)
Abstract Background Combining cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors with endocrine therapy is an effective strategy to improve progression-free survival in hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2
Externí odkaz:
https://doaj.org/article/bad234be41ab4652a35025ddb0681877
Publikováno v:
Gastroenterology Research and Practice, Vol 2012 (2012)
Externí odkaz:
https://doaj.org/article/40dc382e656b465bbe6b7092eab5bfcc
Autor:
C. J. J. Mulder, S. J. Van Den Hazel
Publikováno v:
Mediators of Inflammation, Vol 7, Iss 3, Pp 135-136 (1998)
Mesalazine is widely used in the treatment of inflammatory bowel disease. Little is known about the doseresponse relationship and about possible dose related side effects. In ulcerative colitis higher dosages of mesalazine (3 g) are more effective in
Externí odkaz:
https://doaj.org/article/0af5646798784b44b79f119c1164cc99
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.